Advertisement

Guidelines on Radioisotope Treatment of Liver Cancer and Liver Metastases with Intra-arterial Radioactive Compounds

  • Murat Fani Bozkurt
  • Laura Evangelista
Chapter

Abstract

The present chapter has the aim to provide the current position of radioembolization (RE) for the treatment of primary and secondary liver lesions, in the main national and international clinical guidelines. In Table 16.1, a summary of clinical indications is reported.

References

  1. 1.
    Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251–78.CrossRefPubMedGoogle Scholar
  2. 2.
    Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13–23.CrossRefPubMedGoogle Scholar
  3. 3.
    Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2011;38(7):1393–406.  https://doi.org/10.1007/s00259-011-1812-2.CrossRefPubMedGoogle Scholar
  4. 4.
    Salem R, Lewandowski RJ, Gates VL, Nutting CW, Murthy R, Rose SC, et al. Research reporting standards for radioembolization of hepatic malignancies. J Vasc Interv Radiol. 2011;22:265–78.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–43.CrossRefGoogle Scholar
  7. 7.
    Verslype C, Rosmorduc O, Rougier P. Hepatocellular carcinoma: ESMO-ESDO clinical practice guidelines. Ann Oncol. 2012;23:vii41–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Boily G, Villeneuve J-P, Lacoursière L, Chaudhury P, Couture F, Ouellet J-F, et al. Transarterial embolization therapies for the treatment of hepatocellular carcinoma: CEPO review and clinical recommendations. HPB (Oxford). 2015;17:52–65.CrossRefGoogle Scholar
  9. 9.
    Kennedy A, Bester L, Salem R, Sharma RA, Parks RW, Ruszniewski F. Role of hepatic intra-arterial therapies in metastatic neuroendocrine tumours (NET): guidelines from the NET-Liver-Metastases Consensus Conference. HPB (Oxford). 2015;17:29–37.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Nuclear MedicineHacettepe University Faculty of MedicineAnkaraTurkey
  2. 2.Veneto Institute of Oncology IOV – IRCCSPaduaItaly

Personalised recommendations